Natixis Advisors LLC Has $16.92 Million Position in Insulet Corporation $PODD

Natixis Advisors LLC reduced its position in shares of Insulet Corporation (NASDAQ:PODD) by 10.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 59,524 shares of the medical instruments supplier’s stock after selling 7,188 shares during the period. Natixis Advisors LLC’s holdings in Insulet were worth $16,919,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Larson Financial Group LLC lifted its holdings in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the last quarter. Elyxium Wealth LLC acquired a new stake in Insulet during the 4th quarter worth approximately $28,000. Fideuram Asset Management Ireland dac acquired a new stake in Insulet during the 4th quarter worth approximately $41,000. Measured Wealth Private Client Group LLC acquired a new stake in Insulet during the 3rd quarter worth approximately $49,000. Finally, Osterweis Capital Management Inc. acquired a new stake in Insulet during the 2nd quarter worth approximately $51,000.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. William Blair assumed coverage on Insulet in a report on Wednesday, May 20th. They set an “outperform” rating for the company. Oppenheimer dropped their price objective on Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Jefferies Financial Group dropped their price objective on Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $205.00 price objective on shares of Insulet in a report on Wednesday, May 27th. Finally, TD Cowen dropped their price objective on Insulet from $379.00 to $294.00 and set a “hold” rating for the company in a report on Monday, June 1st. Twenty-one equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $252.04.

Insiders Place Their Bets

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The shares were acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.36% of the stock is owned by corporate insiders.

Insulet Price Performance

Insulet stock opened at $153.22 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. Insulet Corporation has a 52 week low of $140.63 and a 52 week high of $354.88. The stock has a market capitalization of $10.61 billion, a P/E ratio of 35.63, a price-to-earnings-growth ratio of 1.15 and a beta of 1.13. The stock has a fifty day moving average of $175.73 and a 200-day moving average of $238.90.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter in the previous year, the firm earned $1.02 EPS. Insulet’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, sell-side analysts expect that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.